Marc Agronin, M.D., on Treating Agitation in Dementia
The Carlat Psychiatry Report, Volume 3, Number 8, August 2005
Marc Agronin, M.D.
Director of Mental Health Services
Miami Jewish Home & Hospital for the Aged
Assistant Professor of Psychiatry
University of Miami School of Medicine
Dr. Agronin has disclosed that he is the recipient of research grants from Forest Laboratories, Novartis, Ono Pharmaceuticals, Progenics, and Theravance, and is a member of the speakers bureaus for Forest Laboratories, Janssen Pharmaceutica, and Ortho-McNeil. Because of these industry relationships, the editors of The Carlat Report have scrutinized and edited the content of Dr. Agronin’s interview in order to identify and resolve any possible faculty conflicts of interest regarding this educational activity. The author has disclosed that antipsychotics, mood stabilizers, benzodiazepines, and trazodone have not been approved by the U.S. Food and Drug Administration for use in the treatment of agitation. Please consult product labeling for the approved usage of these drugs
TCR: Welcome back to The Carlat Report, Dr. Agronin. You were our expert in October of 2003 when we discussed the diagnosis of dementia, and I understand that since then you have been busy with a new textbook project.